Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation (GERN) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class therapies for cancer. The company's cornerstone product candidate is Imetelstat, a novel telomerase inhibitor currently in clinical development. Telomerase is an enzyme that allows cancer cells to maintain telomere length, essential for limitless cellular replication.
Imetelstat is a potent, specific inhibitor of telomerase and holds promise for treating various hematologic myeloid malignancies. Based on clinical data obtained in late 2012, Geron is exploring the potential of Imetelstat to treat conditions such as myelofibrosis (MF), myelodysplastic syndromes (MDS), and acute myelogenous leukemia (AML).
Geron earns revenue through a mix of collaboration agreements, milestones, royalties, and licensing arrangements. The company is the exclusive developer of Imetelstat and possesses various rights to the drug. Operating as a single segment focused on oncology, Geron is committed to advancing its research to bring effective cancer treatments to market.
Stay updated with the latest news and developments from Geron Corporation to learn more about their groundbreaking research and progress in cancer treatment.
Rhea-AI Summary
Geron Corporation reported business highlights and financial results for 2023, focusing on the potential FDA approval of imetelstat for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS. The company achieved significant milestones in clinical trials and regulatory approvals, positioning itself for a commercial launch in the U.S. and EU. Financially, Geron projects sufficient funding into Q3 2025, with a focus on increasing headcount and commercial preparations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.8%
Tags
-
Rhea-AI Summary
Geron Corporation (GERN) grants non-statutory stock options to newly hired employees as inducements. The options total 397,010 shares at $1.93 per share, with vesting terms over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
-
Rhea-AI Summary
Geron Corporation (GERN) will release its Q4 and full-year 2023 financial results and business highlights on February 28, 2024. The company will host a conference call to discuss the results and a live webcast will be available on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
Rhea-AI Summary
Geron Corporation (GERN) has granted non-statutory stock options to newly hired employees, totaling 895,930 shares, with an exercise price of $1.92 per share. The options have a 10-year term, vesting over four years, and were granted as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
-
Rhea-AI Summary
Geron Corporation (GERN) CEO to participate in fireside chat at B. Riley Securities Virtual Oncology Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
-
Rhea-AI Summary
Geron Corporation (Nasdaq: GERN) has granted non-statutory stock options to purchase an aggregate of 417,490 shares of Geron common stock as inducements to newly hired employees. The stock options were granted on December 20, 2023, at an exercise price of $2.16 per share. Stock options representing an aggregate of 405,000 shares have a 10-year term and vest over four years, while stock options representing an aggregate of 12,490 shares have a 10-year term and vest in full upon achievement of a certain regulatory milestone. All of the stock options were granted as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the stock option agreements covering the grants and Geron’s 2018 Inducement Award Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
Rhea-AI Summary
Geron Corporation (Nasdaq: GERN) announced data from its IMerge Phase 3 clinical trial evaluating telomerase inhibitor imetelstat in lower risk myelodysplastic syndromes patients, presenting significant clinical benefits and safety profile at the ASH Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
-
Rhea-AI Summary
Geron Corporation (GERN) achieves 50% enrollment in Phase 3 IMpactMF clinical trial for imetelstat in relapsed/refractory myelofibrosis patients. Interim analysis expected in H1 2025, final analysis in H1 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
-
Rhea-AI Summary
Geron Corporation (GERN) announced the publication of results from the IMerge Phase 3 trial investigating imetelstat versus placebo in patients with lower risk myelodysplastic syndromes (MDS) relapsed/refractory or ineligible for erythropoiesis stimulating agents (ESAs). The publication in The Lancet validates the study's importance within the field and reaches hematologists and other providers globally with potentially practice-changing results. Imetelstat is currently under regulatory review by the FDA and EMA for approval in transfusion-dependent anemia in patients with lower risk MDS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.53%
Tags
Rhea-AI Summary
Geron Corporation (GERN) appoints Dr. Gaurav Aggarwal, a prominent investor in the life sciences sector, to its Board of Directors. Dr. Aggarwal brings extensive strategic leadership and a demonstrated track record in corporate strategy and capital formation. His appointment is expected to add tremendous value as the company looks forward to a potential commercial launch in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of Geron (GERN)?
The current stock price of Geron (GERN) is $2.99 as of January 22, 2025.
What is the market cap of Geron (GERN)?
The market cap of Geron (GERN) is approximately 1.8B.
What is the primary focus of Geron Corporation?
Geron Corporation is focused on developing first-in-class cancer therapies, particularly a telomerase inhibitor named Imetelstat.
What is Imetelstat?
Imetelstat is a novel, first-in-class telomerase inhibitor developed by Geron Corporation for treating various hematologic myeloid malignancies.
Which conditions is Imetelstat being developed to treat?
Imetelstat is being developed to treat myelofibrosis (MF), myelodysplastic syndromes (MDS), and acute myelogenous leukemia (AML).
How does Imetelstat work?
Imetelstat works by inhibiting telomerase, an enzyme that enables cancer cells to maintain telomere length and replicate indefinitely.
What revenue streams does Geron Corporation rely on?
Geron earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements.
Is Geron Corporation a diversified company?
No, Geron operates as a single segment focused on the development of therapeutic products for oncology.
What is the significance of telomerase in cancer treatment?
Telomerase allows cancer cells to maintain telomere length, which is crucial for their endless replication. Inhibiting telomerase can potentially limit cancer growth.
Has Geron Corporation achieved any significant milestones?
Yes, Geron has obtained promising clinical data for Imetelstat and continues to develop it for various cancer treatments.
Where can I find the latest news about Geron Corporation?
You can find the latest news and developments about Geron Corporation on their official website and dedicated stock market websites like StockTitan.
What makes Imetelstat unique among cancer therapies?
Imetelstat is unique because it is a first-in-class telomerase inhibitor, targeting a critical enzyme that allows cancer cells to replicate indefinitely.
Geron Corp
Nasdaq:GERN
GERN Rankings
GERN Stock Data
1.79B
603.98M
0.09%
85.38%
10.67%
Biotechnology
Pharmaceutical Preparations
United States of America
FOSTER CITY